Want to see GUTS full AI Analyst Report?

Fractyl Health, Inc. (GUTS) Price & Analysis

611 Followers

GUTS Stock Chart & Stats

$0.78

$0.02(2.15%)

At close: Jul 24 4:00 PM EDT

$0.78

$0.02(2.15%)

Day’s Range― - ―

52-Week Range$0.38 - $2.45

Previous Close$1.96

Volume1.77M

Average Volume (3M)1.41M

Market Cap

$113.15M

Enterprise Value$139.63

Total Cash (Recent Filing)$47.14M

Total Debt (Recent Filing)$60.74M

Price to Earnings (P/E)―

Beta0.82

Next Earnings

Nov 18, 2026

EPS Estimate

-0.12

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.10

Shares Outstanding159,179,860

10 Day Avg. Volume1,450,112

30 Day Avg. Volume1,414,212

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)35.68

Price to Sales (P/S)0.00

P/FCF Ratio-3.71

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$4.80

Price Target Upside515.38% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-0.35

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Durable Clinical Efficacy And SafetySustained weight-loss maintenance after a single procedure supports Revita’s potential differentiation from chronic drug therapy. The favorable one-year safety profile may also improve physician adoption and strengthen the basis for broader commercialization.

Strong Pivotal-study ExecutionA large, well-powered pivotal program with high retention reduces execution risk and provides a credible path to decisive evidence. Defined six- and 12-month readouts create important catalysts for regulatory and commercial planning.

Differentiated Commercial PositioningUsing established GI workflows and concentrated centers of excellence could support efficient market entry without requiring a broad infrastructure buildout. A durable alternative to chronic GLP-1 use may address adherence and affordability needs.

Bears Say

Pre-commercial Revenue ProfileThe absence of meaningful revenue confirms that the company remains dependent on clinical progress rather than commercial cash generation. Persistent losses leave profitability highly contingent on regulatory approval, launch execution, and market adoption.

Heavy Cash Burn And Financing RiskOngoing negative cash flow and a limited runway may require external financing before the business becomes self-sustaining. Any pivotal delay, additional development cost, or weak result could increase dilution or constrain strategic flexibility.

Uncertain Regulatory And Reimbursement OutcomesFDA classification and approval are not guaranteed, and reimbursement requirements could narrow the eligible patient population. These uncertainties may delay launch, limit adoption, or reduce the commercial value of otherwise positive clinical results.

Fractyl Health, Inc. News

Fractyl Health reports Q2 EPS (16c), consensus (14c)

“With one-year randomized data for the REMAIN-1 Midpoint Cohort and open label data for REVEAL-1 Cohort, we have...

23d ago

GUTS

Fractyl Health Lawsuit Alleges Revita Disclosures Led to Investor Losses After GUTS Stock Drop

Fractyl Health, Inc. (NASDAQ: GUTS) is facing a federal securities lawsuit alleging that investors were misled about Revita,...

6d ago

GUTS

Fractyl Health Earnings Call Signals Promise Amid Risks

Fractyl Health, Inc. (($GUTS)) has held its Q2 earnings call. Read on for the main highlights of the...

11d ago

GUTS

GUTS Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Fractyl Health, Inc. (GUTS) is scheduled to report 2nd quarter earnings on 08/10/2026, after the market closes. Regarding...

25d ago

GUTS

Hold Rating Reaffirmed as Revita Data Show Promise but Risks and Valuation Keep Price Target Unchanged at $2

Morgan Stanley analyst Michael Ulz maintained a Hold rating on Fractyl Health, Inc. yesterday and set a price...

2M ago

GUTS

Fractyl Health reports results from REMAIN-1 Midpoint Cohort

Fractyl Health (GUTS) announced positive one-year results from its REMAIN-1 Midpoint Cohort. The new results reinforce the potential...

2M ago

GUTS

Craig-Hallum bullish on Fractyl Health, initiates with a Buy

As previously reported, Craig-Hallum initiated coverage of Fractyl Health (GUTS) with a Buy rating and $4 price target...

2M ago

GUTS

Fractyl Health initiated with a Buy at Craig-Hallum

Craig-Hallum initiated coverage of Fractyl Health (GUTS) with a Buy rating and $4 price target Published first on...

2M ago

GUTS

Fractyl Health Stockholders Back Board and Auditor at Meeting

Fractyl Health, Inc. ( ($GUTS) ) has issued an update. On June 10, 2026, Fractyl Health, Inc. held...

3M ago

GUTS

Analyst Reiterates Buy on Fractyl Health as New Revita Data De-Risk Durability; $8 Price Target Maintained

Whitney Ijem, an analyst from Canaccord Genuity, reiterated the Buy rating on Fractyl Health, Inc.. The associated price...

3M ago

GUTS

Fractyl Health Highlights One-Year Revita Obesity Results

Fractyl Health, Inc. ( ($GUTS) ) has provided an announcement. On June 4, 2026, Fractyl Health reported one-year...

3M ago

GUTS

Fractyl Health’s Pivotal Year: Inside the Earnings Call

Fractyl Health, Inc. (($GUTS)) has held its Q1 earnings call. Read on for the main highlights of the...

4M ago

GUTS

Fractyl Health reports Q1 EPS 6c, consensus (16c)

“We believe Revita has the potential to offer a transformational new approach to durable weight maintenance and a...

4M ago

GUTS

Fractyl Health Advances RJVA-001 Gene Therapy Trial

Fractyl Health, Inc. ( ($GUTS) ) has provided an update. On May 11, 2026, Fractyl Health, Inc. announced...

4M ago

GUTS

GUTS FAQ

What was Fractyl Health, Inc.’s price range in the past 12 months?

Fractyl Health, Inc. lowest stock price was $0.38 and its highest was $2.44 in the past 12 months.

What is Fractyl Health, Inc.’s market cap?

Fractyl Health, Inc.’s market cap is $113.15M.

When is Fractyl Health, Inc.’s upcoming earnings report date?

Fractyl Health, Inc.’s upcoming earnings report date is Nov 18, 2026 which is in 77 days.

How were Fractyl Health, Inc.’s earnings last quarter?

Fractyl Health, Inc. released its earnings results on Aug 10, 2026. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.135 by -$0.025.

Is Fractyl Health, Inc. overvalued?

According to Wall Street analysts Fractyl Health, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Fractyl Health, Inc. pay dividends?

Fractyl Health, Inc. does not currently pay dividends.

What is Fractyl Health, Inc.’s EPS estimate?

Fractyl Health, Inc.’s EPS estimate is -0.12.

How many shares outstanding does Fractyl Health, Inc. have?

Fractyl Health, Inc. has 159,179,860 shares outstanding.

What happened to Fractyl Health, Inc.’s price movement after its last earnings report?

Fractyl Health, Inc. reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.135. Following the earnings report the stock price went up 3.852%.

Which hedge fund is a major shareholder of Fractyl Health, Inc.?

Currently, no hedge funds are holding shares in GUTS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Fractyl Health, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

32.21%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Fractyl Health, Inc.

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Fractyl Health, Inc. (GUTS) Earnings & Revenues

Historic Earnings Reports

GUTS Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call emphasized multiple strong clinical signals (robust 1-year randomized results, favorable safety, well-powered pivotal design) and concrete regulatory/reimbursement positioning, supported by cost discipline that extends runway into early 2027. Material risks remain—limited cash runway, ongoing operating losses, and outstanding regulatory and payer determinations—that depend on the upcoming pivotal 6-month readout and subsequent FDA review. On balance, positive clinical and strategic progress outweigh near-term financial and regulatory risks.View all GUTS earnings summaries

GUTS Stock 12 Month Forecast

Average Price Target

$4.80

▲(515.38% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","-1":"-$1","1.5":"$1.5","6.5":"$6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.708,1.2689230769230768,1.8298461538461537,2.3907692307692305,2.9516923076923076,3.5126153846153843,4.073538461538461,4.634461538461538,5.195384615384615,5.756307692307692,6.317230769230768,6.878153846153846,7.4390769230769225,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.708,1.0227692307692307,1.3375384615384616,1.6523076923076923,1.967076923076923,2.2818461538461534,2.5966153846153848,2.9113846153846152,3.2261538461538457,3.540923076923077,3.8556923076923075,4.170461538461538,4.485230769230769,{"y":4.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.708,0.8073846153846154,0.9067692307692308,1.0061538461538462,1.1055384615384616,1.204923076923077,1.3043076923076922,1.4036923076923076,1.503076923076923,1.6024615384615384,1.7018461538461538,1.8012307692307692,1.9006153846153846,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.98,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.23,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.472,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.501,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.464,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.699,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.867,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.782,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.685,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.708,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >